Why the study?
Heart failure management remains limited in improving quality of life and prognosis, prompting interest in understanding HF pathophysiology and the role of SGLT-2 inhibitors in HF and comorbid type 2 diabetes mellitus.
Do SGLT-2 inhibitors improve outcomes in patients with heart failure and type 2 diabetes mellitus?
Do SGLT-2 inhibitors improve outcomes in patients with heart failure and type 2 diabetes mellitus?
This review highlights the pathophysiological rationale and potential clinical benefits of SGLT-2 inhibitors in managing heart failure, particularly in patients with comorbid type 2 diabetes.
Hypothesis-generating for SGLT-2 inhibitors in HF with T2DM; requires RCTs before practice change.
Heart failure (HF) is one of the leading causes of hospital readmissions and health care expenditures. With a vast degree of advancements in the clinical approach and diagnosis, its management protocol is limited in terms of enhancing quality of life and prognosis. Type 2 diabetes mellitus (T2DM) is considered as one of the commonly associated comorbid conditions in the HF population. The understanding of the molecular and metabolic models of HF has led to the utilization of therapeutic goals of T2DM in improving HF-related complications. In the recent era, SGLT-2 inhibitors have shown success in decreasing cardiovascular mortality in the T2DM population. This article will help the reviewer to comprehend the pathophysiology of HF and the potential role of SGLT-2 inhibitors in the management algorithm of HF and its associated risk factors in T2DM.
No takes yet. Share an insight, caveat, or question.
Saad et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: